LYEL — Lyell Immunopharma Income Statement
0.000.00%
Last trade - 00:00- $136.21m
- -$234.32m
- $0.06m
Annual income statement for Lyell Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.76 | 10.7 | 84.7 | 0.13 | 0.061 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 220 | 262 | 277 | 260 | 372 |
| Operating Profit | -212 | -251 | -192 | -260 | -372 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -204 | -250 | -183 | -235 | -343 |
| Net Income After Taxes | -204 | -250 | -183 | -235 | -343 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -204 | -250 | -183 | -235 | -343 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -204 | -250 | -183 | -235 | -343 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.842 | -0.879 | -0.714 | -0.883 | -0.732 |
| Dividends per Share |